Bacterial Vaginosis Treatment
For non-pregnant women with bacterial vaginosis, treat with metronidazole 500 mg orally twice daily for 7 days, which achieves 95% cure rates and is the most effective first-line therapy. 1
Standard Treatment for Non-Pregnant Women
The CDC guidelines establish three equally recommended first-line regimens 1:
- Metronidazole 500 mg orally twice daily for 7 days (preferred - highest cure rate at 95%)
- Metronidazole gel 0.75%, one full applicator (5g) intravaginally once daily for 5 days
- Clindamycin cream 2%, one full applicator (5g) intravaginally at bedtime for 7 days
Important counseling points:
- Avoid alcohol during metronidazole treatment and for 24 hours after completion
- Clindamycin cream is oil-based and weakens latex condoms and diaphragms 1
Alternative Regimens (Lower Efficacy)
Use only when first-line options fail or are contraindicated 1:
- Metronidazole 2g orally single dose (84% cure rate vs 95% for 7-day regimen - less effective) 2
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100g intravaginally at bedtime for 3 days
The vaginal clindamycin cream is notably less efficacious than metronidazole regimens 1.
Treatment During Pregnancy
All symptomatic pregnant women must be tested and treated due to associations with preterm birth, premature rupture of membranes, chorioamnionitis, postpartum endometritis, and post-cesarean wound infections. 1
Recommended Pregnancy Regimens
Use systemic therapy only 1:
- Metronidazole 250 mg orally three times daily for 7 days (lower dose to minimize fetal exposure)
- Clindamycin 300 mg orally twice daily for 7 days
Critical: Do NOT use topical agents during pregnancy. Three trials demonstrated increased adverse events (prematurity and neonatal infections) with clindamycin cream 1. Multiple studies and meta-analyses show no teratogenic or mutagenic effects from metronidazole use in pregnancy 1, 3.
High-Risk Pregnant Women
For women with prior preterm delivery, screening and treatment at the earliest part of the second trimester may reduce preterm delivery risk 1. Treatment before 20 weeks' gestation specifically may reduce preterm birth risk (OR 0.63) 3. However, universal screening of low-risk asymptomatic pregnant women is not supported by evidence 4, 3.
Recurrent Bacterial Vaginosis
Recurrence occurs in up to 50% of women within 6 months to 1 year after initial treatment. 5, 6
Management Algorithm for Recurrence
First recurrence: Use any of the recommended first-line regimens (can switch from initial treatment) 1
Persistent recurrence: Extended metronidazole therapy 5, 6:
- Metronidazole 500 mg orally twice daily for 10-14 days
- If ineffective: Metronidazole gel 0.75% for 10 days, then twice weekly for 3-6 months
Refractory cases: Consider vaginal boric acid as an alternative (cheapest and easiest option when first-line extended therapy fails) 6
Emerging evidence: Recent data (StepUp trial) shows treating male partners with combined oral and topical antibiotics significantly reduces BV recurrence, and ACOG now recommends partner therapy for recurrent BV 7
No long-term maintenance regimen with any therapeutic agent is officially recommended by CDC guidelines 1, though extended suppressive therapy is used in practice for recurrent disease 5.
Why Recurrence Occurs
- Biofilm formation protecting BV-associated bacteria from antimicrobials 5
- Residual infection persistence
- Possible reinfection from sexual partners 5, 7
- Failure to restore protective Lactobacillus species 8
Special Considerations
Allergy or Intolerance to Metronidazole
- Use clindamycin cream or oral clindamycin 1
- Metronidazole gel can be considered for systemic intolerance, but never give metronidazole vaginally to patients with oral metronidazole allergy 1
Partner Treatment
Routine treatment of male sex partners is NOT recommended for initial or uncomplicated BV, as clinical trials show no effect on treatment response or recurrence rates 1. However, for recurrent BV specifically, emerging evidence and updated ACOG guidelines now support partner treatment 7.
Follow-Up
- Unnecessary if symptoms resolve 1
- For pregnant women, consider 1-month follow-up evaluation to confirm treatment success 9
- Advise patients to return if symptoms recur
Common Pitfalls to Avoid
- Do not use topical clindamycin in pregnancy - associated with increased adverse neonatal outcomes 1
- Do not use single-dose metronidazole as first-line - 11% lower cure rate than 7-day regimen 2
- Do not give vaginal metronidazole to patients allergic to oral metronidazole - cross-reactivity occurs 1
- Do not routinely treat partners for initial BV (though consider for recurrent cases) 1, 7
- Do not use probiotics or douching - no data support their use per CDC guidelines 1, though Lactobacillus crispatus products show promise in research for recurrent BV 6, 10